Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

BFSP1 C-terminal domains released by post-translational processing events can alter significantly the calcium regulation of AQP0 water permeability.

Tapodi A, Clemens DM, Uwineza A, Jarrin M, Goldberg MW, Thinon E, Heal WP, Tate EW, Nemeth-Cahalan K, Vorontsova I, Hall JE, Quinlan RA.

Exp Eye Res. 2019 Aug;185:107585. doi: 10.1016/j.exer.2019.02.001. Epub 2019 Feb 18.

2.

PARP inhibition induces Akt-mediated cytoprotective effects through the formation of a mitochondria-targeted phospho-ATM-NEMO-Akt-mTOR signalosome.

Tapodi A, Bognar Z, Szabo C, Gallyas F, Sumegi B, Hocsak E.

Biochem Pharmacol. 2019 Apr;162:98-108. doi: 10.1016/j.bcp.2018.10.005. Epub 2018 Oct 6.

3.

Desethylamiodarone-A metabolite of amiodarone-Induces apoptosis on T24 human bladder cancer cells via multiple pathways.

Bognar Z, Fekete K, Antus C, Hocsak E, Bognar R, Tapodi A, Boronkai A, Farkas N, Gallyas F Jr, Sumegi B, Szanto A.

PLoS One. 2017 Dec 8;12(12):e0189470. doi: 10.1371/journal.pone.0189470. eCollection 2017.

4.

In response: Commentary on clinical significance of CYP2C9-status-guided valproic acid therapy in children.

Monostory K, Bűdi T, Tóth K, Nagy A, Szever Z, Kiss Á, Temesvári M, Háfra E, Tapodi A, Garami M.

Epilepsia. 2016 Aug;57(8):1339-40. doi: 10.1111/epi.13451. No abstract available.

5.

The lipidation profile of aquaporin-0 correlates with the acyl composition of phosphoethanolamine lipids in lens membranes.

Ismail VS, Mosely JA, Tapodi A, Quinlan RA, Sanderson JM.

Biochim Biophys Acta. 2016 Nov;1858(11):2763-2768. doi: 10.1016/j.bbamem.2016.06.026. Epub 2016 Jul 1.

6.

Clinical significance of CYP2C9-status guided valproic acid therapy in children.

Bűdi T, Tóth K, Nagy A, Szever Z, Kiss Á, Temesvári M, Háfra E, Garami M, Tapodi A, Monostory K.

Epilepsia. 2015 Jun;56(6):849-55. doi: 10.1111/epi.13011. Epub 2015 May 13.

7.

Regulation of MKP-1 expression and MAPK activation by PARP-1 in oxidative stress: a new mechanism for the cytoplasmic effect of PARP-1 activation.

Racz B, Hanto K, Tapodi A, Solti I, Kalman N, Jakus P, Kovacs K, Debreceni B, Gallyas F Jr, Sumegi B.

Free Radic Biol Med. 2010 Dec 15;49(12):1978-88. doi: 10.1016/j.freeradbiomed.2010.09.026. Epub 2010 Oct 16.

PMID:
20920579
8.

Prevalent role of Akt and ERK activation in cardioprotective effect of Ca(2+) channel- and beta-adrenergic receptor blockers.

Kovacs K, Hanto K, Bognar Z, Tapodi A, Bognar E, Kiss GN, Szabo A, Rappai G, Kiss T, Sumegi B, Gallyas F Jr.

Mol Cell Biochem. 2009 Jan;321(1-2):155-64. doi: 10.1007/s11010-008-9929-8. Epub 2008 Oct 31.

PMID:
18975057
9.

A novel SOD-mimetic permeability transition inhibitor agent protects ischemic heart by inhibiting both apoptotic and necrotic cell death.

Bognar Z, Kalai T, Palfi A, Hanto K, Bognar B, Mark L, Szabo Z, Tapodi A, Radnai B, Sarszegi Z, Szanto A, Gallyas F Jr, Hideg K, Sumegi B, Varbiro G.

Free Radic Biol Med. 2006 Sep 1;41(5):835-48. Epub 2006 Jun 15.

PMID:
16895804
10.

Pivotal role of Akt activation in mitochondrial protection and cell survival by poly(ADP-ribose)polymerase-1 inhibition in oxidative stress.

Tapodi A, Debreceni B, Hanto K, Bognar Z, Wittmann I, Gallyas F Jr, Varbiro G, Sumegi B.

J Biol Chem. 2005 Oct 21;280(42):35767-75. Epub 2005 Aug 22.

11.

Protective effect of amiodarone but not N-desethylamiodarone on postischemic hearts through the inhibition of mitochondrial permeability transition.

Varbiro G, Toth A, Tapodi A, Bognar Z, Veres B, Sumegi B, Gallyas F Jr.

J Pharmacol Exp Ther. 2003 Nov;307(2):615-25. Epub 2003 Sep 11.

PMID:
12970391
12.

Concentration dependent mitochondrial effect of amiodarone.

Varbiro G, Toth A, Tapodi A, Veres B, Sumegi B, Gallyas F Jr.

Biochem Pharmacol. 2003 Apr 1;65(7):1115-28.

PMID:
12663047
13.

[Surgical methods for the management of impacted upper cuspids].

Tapodi A.

Fogorv Sz. 1989 Jan;82(1):13-6. Hungarian.

PMID:
2912788

Supplemental Content

Loading ...
Support Center